Stock Alert: Vertex Pharma Tanks 15% On Stopping Development Of Protein-deficiency Drug

By RTTNews Staff Writer   ✉   | Published:

Shares of Vertex Pharmaceuticals Incorporated (VRTX) are falling more than 15% Thursday morning after the company said it has decided to stop the development of its protein-deficiency drug candidate VX-814.

VX-814 was in phase II study in patients with alpha-1 antitrypsin deficiency.

Vertex Pharmaceuticals stock is currently at $229.78. It has been trading in the range of $173.62- $306.08 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Previous Story
Next Story
Editors Pick
Tesla Cuts Price Of Model S
Electric car maker Tesla Inc. has cut the price of its Model S Long Range sedan. Chief Executive Elon Musk tweeted, "The gauntlet has been thrown down! The prophecy will be fulfilled. Model S price changes to $69,420 tonight!" Further, in a reply to a tweet, Musk confirmed that Tesla is starting production on Model Y seven seater next month, with plans for initial deliveries in early December.
Morgan Stanley Q3 Profit Up 26%; Results Top Estimates
Financial services firm Morgan Stanley reported Thursday a profit for the third quarter that increased 26 percent from last year, reflecting 16 percent revenue growth amidst strength across all business segments. Both adjusted earnings per share and quarterly net revenues topped analysts' expectations.
Brazil's J&F To Pay $256 Mln, Its Unit JBS SA To Pay $27 Mln In FCPA Violations
Brazilian meat and protein major JBS SA, its parent J&F Investimentos S.A. as well as their owners Joesley Batista and Wesley Batista have agreed to pay fines related to violations of the U.S. Government's Foreign Corrupt Practices Act or FCPA. In order to resolve bribery charges, J&F agreed with the U.S. Department of Justice to pay a criminal monetary penalty of $256.50 million, while JBS agreed